Japan Unit Of AstraZeneca Begins Second-Phase Trials For Lupus Drug
This article was originally published in PharmAsia News
Executive Summary
The Japanese unit of U.K.-based AstraZeneca says it has begun Phase II trials of its MEDI-545 (sifalimumab) drug for treating lupus. The treatment being tested by AstraZeneca KK relies on supplying an antibody for interferon alpha considered to be the cause of lupus in high concentrations. Another AstraZeneca subsidiary, U.S.-based Medimmune, created the drug in 2004 and is developing it through its subsidiaries in Japan, Europe and the United States. (Click here for more - a subscription may be required
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.